Benzodiazepine Dependence

Version	Summary	Created by	Modification	Content Size	Created at	Operation
1	handwiki	Camila Xu	--	5217	2022-11-18 01:38:57

The content is sourced from: https://handwiki.org/wiki/Medicine:Benzodiazepine_dependence

Benzodiazepine dependence defines a situation in which one has developed one or more of either tolerance, withdrawal symptoms, drug seeking behaviors, such as continued use despite harmful effects, and maladaptive pattern of substance use, according to the DSM-IV. In the case of benzodiazepine dependence, however, the continued use seems to be associated with the avoidance of unpleasant withdrawal reaction rather than from the pleasurable effects of the drug. Benzodiazepine dependence develops with long-term use, even at low therapeutic doses, without the described dependence behavior. Addiction consists of people misusing or craving the drug not to relieve withdrawal symptoms, but to experience its euphoric or intoxicating effects. It is necessary to distinguish between addiction to and abuse of benzodiazepines and physical dependence on them. The increased GABA inhibition on the neural systems caused by benzodiazepines is counteracted by the body's development of tolerance to the drug's effects; the development of tolerance occurs as a result of neuroadaptations, which result in decreased GABA activity and increased excitability of the glutamate system; these adaptations occur as a result of the body trying to overcome the central nervous system depressant effects of the drug to restore homeostasis. When benzodiazepines are stopped, these neuroadaptations are "unmasked" leading to hyper-excitability of the nervous system and the appearance of withdrawal symptoms. Therapeutic dose dependence is the largest category of people dependent on benzodiazepines. These individuals typically do not escalate their doses to high levels and generally use their medication as intended by their prescriber. Smaller groups include patients escalating their dosage to higher levels and drug misusers as well. Tolerance develops within days or weeks to the anticonvulsant, hypnotic, muscle relaxant and after 4 months there is little evidence that benzodiazepines retain their anxiolytic properties. Some authors, however, disagree and feel that benzodiazepines retain their anxiolytic properties. Long-term benzodiazepine treatment may remain necessary in certain clinical conditions. Numbers of benzodiazepine prescriptions have been declining, due primarily to concerns of dependence. In the short term, benzodiazepines can be effective drugs for acute anxiety or insomnia. With longer-term use, other therapies, both pharmacological and psychotherapeutic, become more effective. This is in part due to the greater effectiveness over time of other forms of therapy, and also due to the eventual development of pharmacological benzodiazepine tolerance.

physical dependence glutamate anticonvulsant

References

Khong E; Sim MG; Hulse G (Nov 2004). "Benzodiazepine dependence". Aust Fam Physician 33 (11): 923–6. PMID 15584332. http://www.racgp.org.au/afpbackissues/2004/200410/20041031khong.pdf.
National Treatment Agency for Substance Misuse (2007). "Drug misuse and dependence - UK guidelines on clinical management". United Kingdom: Department of Health. http://www.nta.nhs.uk/publications/documents/clinical_guidelines_2007.pdf.
Marriott S; Tyrer P (August 1993). "Benzodiazepine dependence. Avoidance and withdrawal". Drug Safety 9 (2): 93–103. doi:10.2165/00002018-199309020-00003. PMID 8104417. https://dx.doi.org/10.2165%2F00002018-199309020-00003
Madhusoodanan S; Bogunovic OJ (September 2004). "Safety of benzodiazepines in the geriatric population". Expert Opin Drug Saf 3 (5): 485–93. doi:10.1517/14740338.3.5.485. PMID 15335303. https://dx.doi.org/10.1517%2F14740338.3.5.485
Longo LP; Johnson B (April 2000). "Addiction: Part I. Benzodiazepines--side effects, abuse risk and alternatives". Am Fam Physician 61 (7): 2121–8. PMID 10779253. http://www.aafp.org/afp/20000401/2121.html. Retrieved 2009-07-17.
Baillargeon L; Landreville P; Verreault R; Beauchemin JP; Grégoire JP; Morin CM (November 2003). "Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial". CMAJ 169 (10): 1015–20. PMID 14609970. PMC 236226. http://eprints.ucl.ac.uk/6558/1/6558.pdf. Retrieved 2009-07-17.
Allison C; Pratt JA (May 2003). "Neuroadaptive processes in GABAergic and glutamatergic systems in benzodiazepine dependence". Pharmacol. Ther. 98 (2): 171–95. doi:10.1016/S0163-7258(03)00029-9. PMID 12725868. https://dx.doi.org/10.1016%2FS0163-7258%2803%2900029-9
Haddad P; Deakin B; Dursun S (27 May 2004). "Benzodiazepine dependence". Adverse Syndromes and Psychiatric Drugs: A clinical guide. Oxford University Press. pp. 240–252. ISBN 978-0-19-852748-0. https://books.google.com/books?id=uV1rE_hOvJ8C&pg=PA240.
"[Should the duration of treatment be limited using benzodiazepines?]" (in fr). Presse Med 47 (10): 892–898. October 2018. doi:10.1016/j.lpm.2018.10.006. PMID 30454582. https://dx.doi.org/10.1016%2Fj.lpm.2018.10.006
Pétursson H (1994). "The benzodiazepine withdrawal syndrome". Addiction 89 (11): 1455–9. doi:10.1111/j.1360-0443.1994.tb03743.x. PMID 7841856. https://dx.doi.org/10.1111%2Fj.1360-0443.1994.tb03743.x
Galanter M; Kleber HD (1 July 2008). The American Psychiatric Publishing Textbook of Substance Abuse Treatment (4th ed.). United States of America: American Psychiatric Publishing Inc. p. 114. ISBN 978-1-58562-276-4. https://books.google.com/books?id=6wdJgejlQzYC.
Ashton H (2005). "The diagnosis and management of benzodiazepine dependence". Current Opinion in Psychiatry 18 (3): 249–55. doi:10.1097/01.yco.0000165594.60434.84. PMID 16639148. http://www.benzo.org.uk/amisc/ashdiag.pdf.
Heberlein A; Bleich S; Kornhuber J; Hillemacher T (Jan 2009). "[Benzodiazepine dependence: causalities and treatment options]". Fortschr Neurol Psychiatr 77 (1): 7–15. doi:10.1055/s-0028-1100831. PMID 19101875. https://dx.doi.org/10.1055%2Fs-0028-1100831
Potokar J; Coupland N; Wilson S; Rich A; Nutt D (September 1999). "Assessment of GABA(A)benzodiazepine receptor (GBzR) sensitivity in patients on benzodiazepines". Psychopharmacology 146 (2): 180–4. doi:10.1007/s002130051104. PMID 10525753. http://link.springer.de/link/service/journals/00213/bibs/9146002/91460180.htm.
Lader; Morgan; Shepherd; Williams, P; Skegg; Parish; Tyrer Dr, P; Inman et al. (30 October 1980 – 3 April 1981) (PDF). Benzodiazepine dependence : papers, notes and correspondence; report of an ad-hoc meeting held on 23rd September 1981 submitted to Neuro Board in January 1982 and subsequent correspondence (Report). England: The National Archives. http://nationalarchives.gov.uk/catalogue/displaycataloguedetails.asp?CATLN=6&CATID=7798554&j=1.
Koff JM; Pritchard GA; Greenblatt DJ; Miller LG (November 1997). "The NMDA receptor competitive antagonist CPP modulates benzodiazepine tolerance and discontinuation". Pharmacology 55 (5): 217–27. doi:10.1159/000139531. PMID 9399331. https://dx.doi.org/10.1159%2F000139531
Fujita M et al. (March 1999). "Changes of benzodiazepine receptors during chronic benzodiazepine administration in humans". Eur. J. Pharmacol. 368 (2–3): 161–72. doi:10.1016/S0014-2999(99)00013-8. PMID 10193652. https://dx.doi.org/10.1016%2FS0014-2999%2899%2900013-8
Poulos CX; Zack M (2004). "Low-dose diazepam primes motivation for alcohol and alcohol-related semantic networks in problem drinkers". Behavioural Pharmacology 15 (7): 503–12. doi:10.1097/00008877-200411000-00006. PMID 15472572. https://dx.doi.org/10.1097%2F00008877-200411000-00006
Kushner MG; Abrams K; Borchardt C (March 2000). "The relationship between anxiety disorders and alcohol use disorders: a review of major perspectives and findings". Clin Psychol Rev 20 (2): 149–71. doi:10.1016/S0272-7358(99)00027-6. PMID 10721495. https://dx.doi.org/10.1016%2FS0272-7358%2899%2900027-6
Khanna JM; Kalant H; Weiner J; Shah G (1992). "Rapid tolerance and cross-tolerance as predictors of chronic tolerance and cross-tolerance". Pharmacol. Biochem. Behav. 41 (2): 355–60. doi:10.1016/0091-3057(92)90110-2. PMID 1574525. https://dx.doi.org/10.1016%2F0091-3057%2892%2990110-2
World Health Organisation - Assessment of Zopiclone https://www.who.int/medicines/areas/quality_safety/4.6ZopicloneCritReview.pdf
Allan AM; Baier LD; Zhang X (1992). "Effects of lorazepam tolerance and withdrawal on GABAA receptor-operated chloride channels". J. Pharmacol. Exp. Ther. 261 (2): 395–402. PMID 1374467. http://www.ncbi.nlm.nih.gov/pubmed/1374467
Rooke KC (1976). "The use of flurazepam (dalmane) as a substitute for barbiturates and methaqualone/diphenhydramine (mandrax) in general practice". J Int Med Res 4 (5): 355–9. doi:10.1177/030006057600400510. PMID 18375. https://dx.doi.org/10.1177%2F030006057600400510
Reddy DS; Rogawski MA (1 December 2000). "Chronic treatment with the neuroactive steroid ganaxolone in the rat induces anticonvulsant tolerance to diazepam but not to itself". J Pharmacol Exp Ther 295 (3): 1241–8. PMID 11082461. http://jpet.aspetjournals.org/cgi/content/full/295/3/1241.
Martin D; Olsen RW (2000). GABA in the nervous system: the view at fifty. Philadelphia: Lippincott Williams Wilkins. p. 211. ISBN 978-0-7817-2267-4.
Kroboth PD; McAuley JW (1997). "Progesterone: does it affect response to drug?". Psychopharmacol Bull 33 (2): 297–301. PMID 9230647. http://www.ncbi.nlm.nih.gov/pubmed/9230647
Smith SS (2004). Neurosteroid effects in the central nervous system: the role of the GABA-A receptor. Boca Raton, Fla.: CRC Press. pp. 144–145. ISBN 978-0-8493-2392-8.
Rho JM; Sankar R; Cavazos JE (2004). Epilepsy: scientific foundations of clinical practice. New York: M. Dekker. p. 336. ISBN 978-0-8247-5043-5.
Kaltschmidt C; Kaltschmidt B; Baeuerle PA (1995). "Stimulation of ionotropic glutamate receptors activates transcription factor NF-kappa B in primary neurons". Proc. Natl. Acad. Sci. U.S.A. 92 (21): 9618–22. doi:10.1073/pnas.92.21.9618. PMID 7568184. Bibcode: 1995PNAS...92.9618K. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=40853
Humphries P; Pretorius E; Naudé H (2007). "Direct and indirect cellular effects of aspartame on the brain". European Journal of Clinical Nutrition 62 (4): 451–62. doi:10.1038/sj.ejcn.1602866. ISSN 0954-3007. PMID 17684524. https://dx.doi.org/10.1038%2Fsj.ejcn.1602866
"Development of neurotransmitter systems during critical periods". Exp Neurol 190: 8–21. 2004. doi:10.1016/j.expneurol.2004.03.027. PMID 15498537. https://dx.doi.org/10.1016%2Fj.expneurol.2004.03.027
"Synapses". The Brain from Top to Bottom. McGill University. http://thebrain.mcgill.ca/flash/a/a_01/a_01_m/a_01_m_ana/a_01_m_ana.html.
Professor Heather Ashton (2002). "Benzodiazepines: How They Work and How to Withdraw". http://benzo.org.uk/manual/index.htm.
Brown TM; Stoudemire (1998). "Chapter 7 Sedative-Hypnotics and Related Agents". Psychiatric side effects of prescription and over-the-counter medications: recognition and management. USA: American Psychiatric Press Inc. pp. 132–133. ISBN 978-0-88048-868-6. https://books.google.com/books?id=K7kevbILCuQC&pg=RA3-PA137.
Wichniak A; Brunner H; Ising M; Pedrosa Gil F; Holsboer F; Friess E (October 2004). "Impaired hypothalamic-pituitary-adrenocortical (HPA) system is related to severity of benzodiazepine withdrawal in patients with depression". Psychoneuroendocrinology 29 (9): 1101–8. doi:10.1016/j.psyneuen.2003.11.004. PMID 15219633. https://dx.doi.org/10.1016%2Fj.psyneuen.2003.11.004
Biggio G et al. (December 2003). "Molecular mechanisms of tolerance to and withdrawal of GABA(A) receptor modulators". Eur Neuropsychopharmacol 13 (6): 411–23. doi:10.1016/j.euroneuro.2003.08.002. PMID 14636957. https://dx.doi.org/10.1016%2Fj.euroneuro.2003.08.002
Bateson AN (2002). "Basic pharmacologic mechanisms involved in benzodiazepine tolerance and withdrawal". Curr. Pharm. Des. 8 (1): 5–21. doi:10.2174/1381612023396681. PMID 11812247. https://dx.doi.org/10.2174%2F1381612023396681
Follesa P et al. (August 2001). "Increase in expression of the GABA(A) receptor alpha(4) subunit gene induced by withdrawal of, but not by long-term treatment with, benzodiazepine full or partial agonists". Brain Res. Mol. Brain Res. 92 (1–2): 138–48. doi:10.1016/S0169-328X(01)00164-4. PMID 11483250. https://dx.doi.org/10.1016%2FS0169-328X%2801%2900164-4
Polmear A (31 March 2008). Evidence-Based Diagnosis in Primary Care: Practical Solutions to Common Problems. United Kingdom: Butterworth-Heinemann. pp. 346–347. ISBN 978-0-7506-4910-0. https://books.google.com/books?id=LiXjoOQE-VkC&pg=PA346.
ICD-10 (2007). "Chapter V - Mental and behavioural disorders (F00-F99) - Mental and behavioural disorders due to psychoactive substance use, 10-F19)". World Health Organisation. http://apps.who.int/classifications/apps/icd/icd10online/?gf10.htm+f13.
Authier N; Balayssac D; Sautereau M; Zangarelli A; Courty P; Somogyi AA; Vennat B; Llorca PM et al. (Nov 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Ann Pharm Fr 67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604. https://dx.doi.org/10.1016%2Fj.pharma.2009.07.001
Tyrer P, ed (24 January 2008). "Treatment of sedative-hypnotic dependence". Cambridge Textbook of Effective Treatments in Psychiatry (1st ed.). Cambridge University Press. pp. 402. ISBN 978-0-521-84228-0. https://books.google.com/books?id=HLPXELjTgdEC&pg=PA402.
Karch SB (20 December 2006). Drug Abuse Handbook (2nd ed.). United States of America: CRC Press. p. 617. ISBN 978-0-8493-1690-6. https://books.google.com/books?id=F0mUte90ATUC.
Committee on the Review of Medicines (March 29, 1980). "Systematic review of the benzodiazepines. Guidelines for data sheets on diazepam, chlordiazepoxide, medazepam, clorazepate, lorazepam, oxazepam, temazepam, triazolam, nitrazepam, and flurazepam. Committee on the Review of Medicines". Br Med J 280 (6218): 910–2. doi:10.1136/bmj.280.6218.910. PMID 7388368. “ ...the committee concluded that, on the present available evidence, the true addiction potential of benzodiazepines was low. The number dependent on the benzodiazepines in the UK from 1960 to 1977 has been estimated to be 28 persons. This is equivalent to a dependence rate of 5-10 cases per million patient months. ” http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=1601049
Casati A; Sedefov R; Pfeiffer-Gerschel T (2012). "Misuse of medicines in the European Union: a systematic review of the literature". Eur Addict Res 18 (5): 228–45. doi:10.1159/000337028. PMID 22572594. https://dx.doi.org/10.1159%2F000337028
Authier N; Balayssac D; Sautereau M; Zangarelli A; Courty P; Somogyi AA; Vennat B; Llorca PM et al. (Nov 2009). "Benzodiazepine dependence: focus on withdrawal syndrome". Ann Pharm Fr 67 (6): 408–13. doi:10.1016/j.pharma.2009.07.001. PMID 19900604. https://dx.doi.org/10.1016%2Fj.pharma.2009.07.001
Panus P; Katzung BG; Jobst EE; Tinsley S; Masters SB; Trevor AJ (November 2008). "Sedative-hypnotic drugs". Pharmacology for the Physical Therapist (1 ed.). McGraw-Hill Medical. p. 192. ISBN 978-0-07-146043-9. https://books.google.com/books?id=ijbNEiFbaTwC&pg=PA182.
Puri BK; Tyrer P (28 August 1998). "Clinical psychopharmacology". Sciences Basic to Psychiatry (2nd ed.). Churchill Livingstone. pp. 155–157. ISBN 978-0-443-05514-0. https://books.google.com/books?id=KTbfRIqjLtUC&pg=PA149. Retrieved 2009-07-11.
Tyrer P, ed (24 January 2008). Cambridge Textbook of Effective Treatments in Psychiatry (1st ed.). Cambridge University Press. p. 532. ISBN 978-0-521-84228-0. https://books.google.com/books?id=HLPXELjTgdEC.
Morgan K; Dixon S; Mathers N; Thompson J; Tomeny M (February 2004). "Psychological treatment for insomnia in the regulation of long-term hypnotic drug use". Health Technol Assess (National Institute for Health Research) 8 (8): iii-iv, 1–68. doi:10.3310/hta8080. PMID 14960254. https://dx.doi.org/10.3310%2Fhta8080
Baillargeon L; Landreville P; Verreault R; Beauchemin JP; Grégoire JP; Morin CM (November 2003). "Discontinuation of benzodiazepines among older insomniac adults treated with cognitive-behavioural therapy combined with gradual tapering: a randomized trial". CMAJ 169 (10): 1015–20. PMID 14609970. PMC 236226. http://www.cmaj.ca/cgi/content/full/169/10/1015.
Gosselin P; Ladouceur R; Morin CM; Dugas MJ; Baillargeon L (October 2006). "Benzodiazepine discontinuation among adults with GAD: A randomized trial of cognitive-behavioral therapy". J Consult Clin Psychol 74 (5): 908–19. doi:10.1037/0022-006X.74.5.908. PMID 17032095. https://dx.doi.org/10.1037%2F0022-006X.74.5.908
Morgan JD; Wright DJ; Chrystyn H (December 2002). "Pharmacoeconomic evaluation of a patient education letter aimed at reducing long-term prescribing of benzodiazepines". Pharm World Sci 24 (6): 231–5. doi:10.1023/A:1021587209529. PMID 12512155. http://www.kluweronline.com/art.pdf?issn=0928-1231&volume=24&page=231.
Stewart R; Niessen WJ; Broer J; Snijders TA; Haaijer-Ruskamp FM; Meyboom-De Jong B (October 2007). "General Practitioners reduced benzodiazepine prescriptions in an intervention study: a multilevel application". J Clin Epidemiol 60 (10): 1076–84. doi:10.1016/j.jclinepi.2006.11.024. PMID 17884604. https://dx.doi.org/10.1016%2Fj.jclinepi.2006.11.024
Niessen WJ; Stewart RE; Broer J; Haaijer-Ruskamp FM (February 2005). "Vermindering van gebruik van benzodiazepinen door een brief van de eigen huisarts aan chronische gebruikers" (in nl). Ned Tijdschr Geneeskd 149 (7): 356–61. PMID 15751808. http://www.ncbi.nlm.nih.gov/pubmed/15751808
Faccini, Marco; Leone, Roberto; Opri, Sibilla; Casari, Rebecca; Resentera, Chiara; Morbioli, Laura; Conforti, Anita; Lugoboni, Fabio (October 2016). "Slow subcutaneous infusion of flumazenil for the treatment of long-term, high-dose benzodiazepine users: a review of 214 cases". Journal of Psychopharmacology 30 (10): 1047–1053. doi:10.1177/0269881116647505. ISSN 1461-7285. PMID 27166362. https://dx.doi.org/10.1177%2F0269881116647505
Tamburin, Stefano; Faccini, Marco; Casari, Rebecca; Federico, Angela; Morbioli, Laura; Franchini, Enrica; Bongiovanni, Luigi Giuseppe; Lugoboni, Fabio (October 2017). "Low risk of seizures with slow flumazenil infusion and routine anticonvulsant prophylaxis for high-dose benzodiazepine dependence". Journal of Psychopharmacology 31 (10): 1369–1373. doi:10.1177/0269881117714050. ISSN 1461-7285. PMID 28613124. https://dx.doi.org/10.1177%2F0269881117714050
Ashton CH (1997). "Benzodiazepine Dependency". in Baum A. Cambridge Handbook of Psychology & Medicine. England: Cambridge University Press. pp. 376–80. http://www.benzo.org.uk/bzdep.htm.
Anthierens S; Habraken H; Petrovic M; Christiaens T (December 2007). "The lesser evil? Initiating a benzodiazepine prescription in general practice: a qualitative study on GPs' perspectives". Scand J Prim Health Care 25 (4): 214–9. doi:10.1080/02813430701726335. PMID 18041658. PMC 3379762. http://pdfserve.informaworld.com/491348__783865453.pdf.
Granados Menéndez MI; Salinero Fort MA; Palomo Ancillo M; Aliaga Gutiérrez L; García Escalonilla C; Ortega Orcos R (2006). "Adecuacion del uso de las benzodiacepinas zolpidem y zopiclona en problemas atendidos en atencion primaria" (in es). Aten Primaria 38 (3): 159–64. doi:10.1157/13090980. PMID 16945275. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=7679814
Barthelmé B; Poirot Y (November 2008). "Niveau d'anxiété et de dépendance des primoconsommants d'anxiolytiques : une étude de psychométrie" (in fr). Presse Med 37 (11): 1555–60. doi:10.1016/j.lpm.2007.10.019. PMID 18502091. https://dx.doi.org/10.1016%2Fj.lpm.2007.10.019
Licata SC; Rowlett JK (2008). "Abuse and dependence liability of benzodiazepine-type drugs: GABA(A) receptor modulation and beyond.". Pharmacology Biochemistry and Behavior 90 (1): 74–89. doi:10.1016/j.pbb.2008.01.001. PMID 18295321. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=2453238
Davies, James; Rae, Todd; Montague, Luke (17 July 2017). "Long-term benzodiazepine and Z-drugs use in the UK: a survey of general practice". British Journal of General Practice 67 (662): e609–e613. doi:10.3399/bjgp17X691865. PMID 28716996. http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pmcentrez&artid=5569740
Fruensgaard K (February 1976). "Withdrawal psychosis: a study of 30 consecutive cases". Acta Psychiatr Scand 53 (2): 105–18. doi:10.1111/j.1600-0447.1976.tb00065.x. PMID 3091. https://dx.doi.org/10.1111%2Fj.1600-0447.1976.tb00065.x
Lader M (1991). "History of benzodiazepine dependence". Journal of Substance Abuse Treatment 8 (1–2): 53–9. doi:10.1016/0740-5472(91)90027-8. PMID 1675692. https://dx.doi.org/10.1016%2F0740-5472%2891%2990027-8
Lucki I; Kucharik RF (1990). "Increased sensitivity to benzodiazepine antagonists in rats following chronic treatment with a low dose of diazepam". Psychopharmacology 102 (3): 350–6. doi:10.1007/BF02244103. PMID 1979180. https://dx.doi.org/10.1007%2FBF02244103
Rickels K; Case WG; Schweizer EE; Swenson C; Fridman RB (1986). "Low-dose dependence in chronic benzodiazepine users: a preliminary report on 119 patients". Psychopharmacology Bulletin 22 (2): 407–15. PMID 2877472. http://www.ncbi.nlm.nih.gov/pubmed/2877472
Lader M (December 1987). "Long-term anxiolytic therapy: the issue of drug withdrawal". The Journal of Clinical Psychiatry 48: 12–6. PMID 2891684. http://www.ncbi.nlm.nih.gov/pubmed/2891684
Miura S; Murasaki M (March 1992). "The future of 5-HT1A receptor agonists. (Aryl-piperazine derivatives)". Progress in Neuro-Psychopharmacology & Biological Psychiatry 16 (6): 833–45. doi:10.1016/0278-5846(92)90103-L. PMID 1355301. https://dx.doi.org/10.1016%2F0278-5846%2892%2990103-L
Meier PJ; Ziegler WH; Neftel K (March 19, 1988). "Benzodiazepine--Praxis und Probleme ihrer Anwendung". Schweizerische medizinische Wochenschrift 118 (11): 381–92. PMID 3287602. http://www.ncbi.nlm.nih.gov/pubmed/3287602
Tsuji K; Tajima O (January 2012). "[Anxiolytic]" (in ja). Nippon Rinsho 70 (1): 42–6. PMID 22413490. http://www.ncbi.nlm.nih.gov/pubmed/22413490
Linden M; Bär T; Geiselmann B (May 1998). "Patient treatment insistence and medication craving in long-term low-dosage benzodiazepine prescriptions". Psychological Medicine 28 (3): 721–9. doi:10.1017/S0033291798006734. PMID 9626728. https://dx.doi.org/10.1017%2FS0033291798006734
Tyrer P (1993). "Benzodiazepine dependence: a shadowy diagnosis". Biochemical Society Symposium 59: 107–19. PMID 7910738. http://www.ncbi.nlm.nih.gov/pubmed/7910738
Karch SB (20 December 2006). Drug Abuse Handbook (2nd ed.). USA: CRC Press. p. 35. ISBN 978-0-8493-1690-6. https://books.google.com/books?id=F0mUte90ATUC.
Dièye AM et al. (2007). "Prescription des benzodiazepines par les medecins generalistes du prive a Dakar: Enquete sur les connaissances et les attitudes" (in fr). Thérapie 62 (2): 163–8. doi:10.2515/therapie:2007018. PMID 17582318. https://dx.doi.org/10.2515%2Ftherapie%3A2007018
Dièye AM; Sylla M; Ndiaye A; Ndiaye M; Sy GY; Faye B (June 2006). "Benzodiazepines prescription in Dakar: a study about prescribing habits and knowledge in general practitioners, neurologists and psychiatrists". Fundam Clin Pharmacol 20 (3): 235–8. doi:10.1111/j.1472-8206.2006.00400.x. PMID 16671957. http://www3.interscience.wiley.com/journal/118553133/abstract.
Woody GE; Mc Lellan AT; O'Brien CP (1979). "Development of psychiatric illness in drug abusers. Possible role of drug preference". The New England Journal of Medicine 301 (24): 1310–4. doi:10.1056/NEJM197912133012403. PMID 41182. https://dx.doi.org/10.1056%2FNEJM197912133012403
Sheehan MF; Sheehan DV; Torres A; Coppola A; Francis E (1991). "Snorting benzodiazepines". Am J Drug Alcohol Abuse 17 (4): 457–68. doi:10.3109/00952999109001605. PMID 1684083. https://dx.doi.org/10.3109%2F00952999109001605
Wetterling T; Backhaus J; Junghanns K (September 2002). "Sucht im Alter Ein unterschätztes Problem in der klinischen Versorgung älterer Menschen?" (in de). Nervenarzt 73 (9): 861–6. doi:10.1007/s00115-002-1359-3. PMID 12215877. https://dx.doi.org/10.1007%2Fs00115-002-1359-3

©Text is available under the terms and conditions of the Creative Commons-Attribution ShareAlike (CC BY-SA) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.

Upload a video for this entry

Information

Subjects: Others

Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register :

HandWiki

View Times: 2.8K

Entry Collection: HandWiki

Update Date: 18 Nov 2022

Table of Contents

Video Upload Options

References